Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy

Mathew Zachariah, Mohamed Elshinawy, Abdulhakim Alrawas, Wafa Bashir, Ismail Elbeshlawi, Surekha Tony, Yasser Wali

Research output: Contribution to journalArticle

1 Citation (Scopus)


The role of erythropoiesis-stimulating agents (ESAs) in the management of chemotherapy-induced anemia (CIA) is becoming increasingly recognized in the field of medical oncology, with paucity of data in pediatrics. We evaluated the efficacy and tolerability of a single-dose darbepoetin alfa, a long-acting ESA, given to 35 pediatric acute lymphoblastic leukemia (ALL) children during induction chemotherapy. Compared to a retrospective control group, the studied patients have required significantly less units of packed red blood cells (0.88 units/patient in the studied group versus 2.04 units in controls), with no major side effects. We recommend further prospective double-blinded studies with more tailored dosing regimens in pediatric ALL cases and solid tumors.

Original languageEnglish
Pages (from-to)442-447
Number of pages6
JournalPediatric Hematology and Oncology
Issue number5
Publication statusPublished - 2014



  • Anemia
  • Chemotherapy
  • Darbepoetin alfa
  • Leukemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Medicine(all)

Cite this